Bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal). NICE technology appraisal guidance 353
National Institute for Health and Care Excellence (NICE)
Record ID 32018011463
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta353
Year Published:
2015
URL for published report:
https://www.nice.org.uk/guidance/ta353
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Bevacizumab
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.